INCREASING THE INFORMATION CONTENT OF A COMMERCIAL TISSUE OXIMETER

增加商用组织血氧计的信息内容

• 批准号: 8362673
• 负责人: ALBERT Edward CERUSSI
• 金额: $ 0.51万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8362673
• 关键词: Biomedical Technology; Biotechnology; Collaborations; Frequencies; Funding; Grant; Hemorrhage; Injury; Institutes; Lasers; Light; Miniaturization; Modeling; Monitor; Morbidity - disease rate; National Center for Research Resources; Optical Methods; Optics; Phase; Photons; Principal Investigator; Production; Research; Research Infrastructure; Resources; Source; Therapeutic Intervention; Tissues; United States National Institutes of Health; Universities; Validation; cost; experience; instrument; migration; mortality; phase 2 study; point of care

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The early recognition of severe hemorrhage is a key factor towards reducing mortality and morbidity from battlefield insults. Although near-infrared (NIR) instruments have shown promise in recognizing hemorrhage, specific confounding factors must be solved to be reliable in early hemorrhage. Our hypothesis is that these confounding factors can be eliminated by proper light-tissue interaction modeling (frequency-domain photon migration), and by increasing spectral (1000 wavelengths) and temporal (200 ms) bandwidth. The objective of this proposal is to provide a compact point-of-care NIR instrument that is capable of quantitatively detecting early hemorrhage and monitoring therapeutic interventions. Our proposal features collaboration between (1) a leading biomedical technology company (ISS, Inc., Champaign, IL) that produces state-of-the-art NIR tissue oximeters, operates production facilities and has FDA submission experience, and (2) a university research team (Beckman Laser Institute, UC Irvine), with tissue optics experts who have experience in the assessment of traumatic injury via NIR optical methods. The existing ISS oximeter will be modified to increase information content that will solve the confounding factors. At the conclusion of Phase I, we will provide a unique NIR instrument that will be available for comprehensive validation and optimization studies (Phase II) and subsequent commercial miniaturization (Phase III).

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 早期识别严重出血是降低战场损伤死亡率和发病率的关键因素。 虽然近红外（NIR）仪器在识别出血方面显示出了希望，但必须解决特定的混杂因素才能在早期出血中可靠。 我们的假设是，这些混杂因素可以消除适当的光组织相互作用建模（频域光子迁移），并通过增加光谱（1000波长）和时间（200毫秒）带宽。 本提案的目的是提供一种紧凑的床旁近红外仪器，能够定量检测早期出血和监测治疗干预。 我们的提案包括（1）一家领先的生物医学技术公司（ISS，Inc.，伊利诺伊州尚潘），生产最先进的近红外组织血氧仪，运营生产设施并拥有FDA提交经验，以及（2）大学研究团队（加州大学欧文分校贝克曼激光研究所），拥有组织光学专家，他们在通过近红外光学方法评估创伤性损伤方面拥有丰富的经验。 将对现有的ISS血氧计进行修改，以增加解决混杂因素的信息内容。 在第一阶段结束时，我们将提供一种独特的近红外仪器，可用于全面的验证和优化研究（第二阶段）以及随后的商业小型化（第三阶段）。